Clinical Trial Details

A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study of NNZ-2566 in Patients with Traumatic Brain Injury (TBI) Protocol NO: Neu-2566-TBI-001
Study Purpose
The purpose of this study is primarily to assess the safety of the new investigational drug, NNZ-2566, in human subjects with TBI. . An additional purpose of the study is to find out if NNZ-2566 improves abnormal brain electrical activity and reduces or prevents brain seizures in the acute stage of TBI.
Study Plan
Intravenous Infusion of the study drug or Placebo: . Neither you nor the study doctors will know which experimental medication you received until the study is completed.

Principal Investigator
Andrew J. Kerwin, M.D., FACS

Sub Investigator
Indermeet S. Bhullar, M.D.

Sub Investigator
J. B. Burns Jr., D.O., M.S.

Sub Investigator
Christopher Y. Hopkins, M.D.
Emergency Medicine

Sub Investigator
Jin H. Ra, M.D.

Sub Investigator
Joseph J. Tepas III, M.D.

News & Announcements

Volunteers bring love to UF Health Jacksonville


Volunteers like Dolores Simmons-Hallmark don’t just seem like a part of the staff at UF Health Jacksonville – they seem lik... [full story]

70 faculty members selected as exemplary teachers


University of Florida College of Medicine – Jacksonville has named the faculty members selected for recognition this year as exem... [full story]

Lung cancer team works together from one unique patient to the next


We examine ourselves for breast cancer, wear sunscreen to prevent skin cancer and undergo colonoscopies to check for colorectal cancer,... [full story]

Upcoming Events

There are currently no events to display. Check back soon!